Riding bikes really far to cure ALS (Lou Gehrig's Disease).
A special note from Chuck & Gabe
Steve Saling. We're riding (again!) for you, buddy!
From July 18 to July 20, four of us will be participating in the "Tri-State Trek," a three-day, 270 mile bike ride from Boston to New York to benefit the ALS Therapy Development Institute, the world's leading ALS research center. ALS, also known as Lou Gehrig's disease, is a neurodegenerative disorder that paralyzes the entire body and disables the speech of the patient while leaving the mind intact. Roughly 350,000 patients are afflicted with the disease worldwide, and following diagnosis, the average ALS patient survives two to five years.
Steve Saling is a friend of ours who was diagnosed with ALS in the fall of 2006. When he first told us that he was diagnosed, we were unaware of what the diagnosis meant for him in the short and long term future. Since then, the more we have learned about ALS the more eager we've become to support the efforts to combat it. Steve's ongoing goal since he was diagnosed has been to enjoy every single day to the fullest and to help those in the ALS community to do the same. His positive attitude has been a true inspiration for us and everyone who has met him, and we've included a link to Steve's website below to give you an idea of how we have been personally touched by the plight of the ALS community and what has inspired us to do something about it.
The Trek is about overcoming challenges and obstacles. It is about inspiring ourselves and inspiring others. It is about pushing beyond our own comfort zone physically, mentally, emotionally, and above all to raise money and awareness for ALS and the ALS TDI. The link below provides more information about the event.
For this event, we have challenged ourselves to raise a minimum of $8,000 as a team. With your support, we can reach and exceed this goal and get one step closer to a cure for ALS.
THANK YOU for helping us reach this goal and THANK YOU for joining us in the battle against ALS.
Chuck McNamee, Glen Harnish, Ben Cohen Leadholm, and Matt Zahler
